Clinical observation of semaglutide combined with empagliflozin in treatment of obese type 2 diabetes
Objective To explore the therapeutic effect of semaglutide combined with empagliflozin in treatment of obese type 2 diabetes.Methods Patients(199 cases)with obese type 2 diabetes in the Second Affiliated Hospital of Xi'an Jiaotong University from September 2022 to December 2023 were divided into control(99 cases)and treatment(100 cases)group based on different treatments.Patients in the control group were po administered with Empagliflozin Tablets,10 mg/time,once daily.Patients in the treatment group were sub-cutaneous administered with Semaglutide Injection,0.25 mg/week for the first 4 weeks,0.5 mg/week for 5-8 weeks,and 1 mg/week from week 9,once weekly.Patients in two groups were treated for 12 weeks.After treatment,the clinical evaluations were evaluated,the scores of DSC-R and DSQL,the levels of blood glucose indexes HbA1c,FBG and 2 h PG,and the levels of blood lipid indexes TC,TG and HDL-C in two groups before and after treatment were compared.Results After treatment,the total clinical effective rates in the control group and the treatment group were 85.86%and 97.00%,respectively,and the difference between the two groups was statistically significant(P<0.05).After treatment,the DSC-R and DSQL scores in the treatment group were significantly decreased(P<0.05),and the score of the treatment group was significantly better than that of the control group(P<0.05).After treatment,the blood glucose indicators HbA1c,FBG,and 2 h PG levels in two groups were significantly decreased compared with those before treatment(P<0.05),and the blood glucose indicators in the treatment group were significantly better than those in the control group(P<0.05).After treatment,the levels of blood lipids TC and TG in two groups were significantly decreased compared with those before treatment,while HDL-C was significantly increased(P<0.05),and the blood lipids in the treatment group were significantly better than those in the control group(P<0.05).Conclusion Smeglutide combined with empagliflozin has a significant therapeutic effect in the treatment of obese type 2 diabetes,which can not only significantly improve the burden of symptoms and quality of life of patients,but also promote the recovery of glucose and lipid metabolism indicators.
Semaglutide InjectionEmpagliflozin Tabletsobesity type 2 diabetesDSQLblood glucoseblood lipid
万方数据
